Aprea Therapeutics (APRE) Non-Current Assets (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Non-Current Assets of $366947.0 for Q1 2026, down 5.35% year-over-year from $387673.0 in Q1 2025, and down 1.4% quarter-over-quarter from $372155.0 in Q4 2025.
Aprea Therapeutics (APRE) Non-Current Assets (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Non-Current Assets for 9 consecutive years, with $366947.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 5.35% year-over-year to $366947.0; the TTM figure through Mar 2026 stood at $1.5 million (down 6.67% YoY), while the FY2025 annual figure was $372155.0, down 7.73% from the prior year.
- Non-Current Assets retreated to $366947.0 in Q1 2026 per APRE's latest filing, from $372155.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $410149.0 in Q3 2024 and bottomed at $1912.0 in Q1 2023.
- Historically, Non-Current Assets has averaged $246985.3 across 5 years, with a median of $292139.0 in 2022.
- Annual changes were most pronounced in 2023 — Non-Current Assets sank 99.35% — and 2024, when it surged 6760.3%.
- Aprea Therapeutics' Non-Current Assets stood at $2321.0 in 2022, then soared by 5461.35% to $129079.0 in 2023, then surged by 212.49% to $403354.0 in 2024, then decreased by 7.73% to $372155.0 in 2025, then decreased by 1.4% to $366947.0 in 2026.
- Business Quant data shows APRE's Non-Current Assets at $366947.0 in Q1 2026, $372155.0 in Q4 2025, and $377328.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | Aprea Therapeutics | 33.32 Mn | 33.32 Mn | - | 376,810.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 376,810.00 |
| Mar 31, 2026 | 366,947.00 |
| Dec 31, 2025 | 372,155.00 |
| Sep 30, 2025 | 377,328.00 |
| Jun 30, 2025 | 382,500.00 |
| Mar 31, 2025 | 387,673.00 |
| Dec 31, 2024 | 403,354.00 |
| Sep 30, 2024 | 410,149.00 |
| Jun 30, 2024 | 404,801.00 |
| Mar 31, 2024 | 131,169.00 |
| Dec 31, 2023 | 129,079.00 |
| Sep 30, 2023 | 126,647.00 |
| Jun 30, 2023 | 41,867.00 |
| Mar 31, 2023 | 1,912.00 |
| Dec 31, 2022 | 2,321.00 |
| Sep 30, 2022 | 148,125.00 |
| Jun 30, 2022 | 220,584.00 |
| Mar 31, 2022 | 292,139.00 |
| Dec 31, 2021 | 239,053.00 |
| Sep 30, 2021 | 305,527.00 |